Skip to main content
. 2014 Jan 2;3(1):e87. doi: 10.1038/psp.2013.63

Figure 1.

Figure 1

Serum trastuzumab concentration–time profiles after subcutaneous (s.c.) or intravenous (i.v.) administration. (a) Individual serum trastuzumab concentration–time profiles after s.c. or i.v. administration of a 6 mg/kg dose to healthy subjects. (b) Median serum trastuzumab concentration–time profiles normalized by dose after s.c. administration of various doses in healthy subjects or patients with early breast cancer (EBC).